These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16273791)

  • 1. Laboratory monitoring of biologic therapies.
    Cush JJ; Yazici Y
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S90-2. PubMed ID: 16273791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
    Fleishmann RM
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
    Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
    Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety issues and concerns of new immunomodulators in rheumatology.
    Selmi C; Ceribelli A; Naguwa SM; Cantarini L; Shoenfeld Y
    Expert Opin Drug Saf; 2015 Mar; 14(3):389-99. PubMed ID: 25518908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side effects of anti-TNF therapy: current knowledge.
    Antoni C; Braun J
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S152-7. PubMed ID: 12463468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy.
    Valesini G; Montecucco C; Cutolo M
    Clin Exp Rheumatol; 2006; 24(4):413-23. PubMed ID: 16956432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of benefit/risk of biological agents.
    Imperato AK; Bingham CO; Abramson SB
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S108-14. PubMed ID: 15552523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of biologic therapies--an update.
    Keystone EC
    J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
    Koike R; Takeuchi T; Eguchi K; Miyasaka N;
    Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
    Hochberg MC; Lebwohl MG; Plevy SE; Hobbs KF; Yocum DE
    Semin Arthritis Rheum; 2005 Jun; 34(6):819-36. PubMed ID: 15942917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring of clinical course in TNF inhibitor treatment for rheumatoid arthritis--efficacy evaluation, adverse effect detection, and prediction of clinical response].
    Yamamura M
    Nihon Rinsho; 2007 Jul; 65(7):1269-75. PubMed ID: 17642242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.